Key result
Isoproterenol-induced cardiac fibrosis is associated with increased CDK1 levels in fibroblasts, regulated by a novel beta-adrenergic response element and NF-Y binding.
Identification of a novel beta-adrenergic response element regulating CDK1 expression in cardiac fibroblasts suggests that targeting CDK1 or NF-Y may inhibit cardiac fibrosis.
Cardiac fibrosis, a known risk factor for heart disease, is typically caused by uncontrolled proliferation of fibroblasts and excessive deposition of extracellular matrix proteins in the myocardium. Cyclin-dependent kinase 1 (CDK1) is involved in the control of G2/M transit phase of the cell cycle. Here, we showed that isoproterenol (ISO)-induced cardiac fibrosis is associated with increased levels of CDK1 exclusively in fibroblasts in the adult mouse heart. Treatment of primary embryonic ventricular cell cultures with ISO (a nonselective β-adrenergic receptor agonist) increased CDK1 protein expression in fibroblasts and promoted their cell cycle activity. Quantitative PCR analysis confirmed that ISO increases CDK1 transcription in a transient manner. Further, the ISO-responsive element was mapped to the proximal -100-bp sequence of the CDK1 promoter region using various 5'-flanking sequence deletion constructs. Sequence analysis of the -100-bp CDK1 minimal promoter region revealed two putative nuclear factor-Y (NF-Y) binding elements. Overexpression of the NF-YA subunit in primary ventricular cultures significantly increased the basal activation of the -100-bp CDK1 promoter construct but not the ISO-induced transcription of the minimal promoter construct. In contrast, dominant negative NF-YA expression decreased the basal activity of the minimal promoter construct and ISO treatment fully rescued the dominant negative effects. Furthermore, site-directed mutagenesis of the distal NF-Y binding site in the -100-bp CDK1 promoter region completely abolished both basal and ISO-induced promoter activation of the CDK1 gene. Collectively, our results raise an exciting possibility that targeting CDK1 or NF-Y in the diseased heart may inhibit fibrosis and subsequently confer cardioprotection.
No takes yet. Share an insight, caveat, or question.
Gaspard et al. (2014) studied Cardiac fibrosis. Isoproterenol was evaluated on CDK1 protein expression and cell cycle activity. Isoproterenol-induced cardiac fibrosis is associated with increased CDK1 levels in fibroblasts, regulated by a novel beta-adrenergic response element and NF-Y binding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from AJP Cell Physiology